Galectin‑7 is elevated in endometrioid (type I) endometrial cancer and promotes cell migration

Menkhorst,Ellen; Griffiths,Meaghan; Van Sinderen,Michelle; Rainczuk,Kate; Niven,Keith; Dimitriadis,Evdokia

doi:10.3892/ol.2018.9193

Galectin‑7 is elevated in endometrioid (type I) endometrial cancer and promotes cell migration

Authors:
- Ellen Menkhorst
- Meaghan Griffiths
- Michelle Van Sinderen
- Kate Rainczuk
- Keith Niven
- Evdokia Dimitriadis
View Affiliations

Affiliations: Centre for Reproductive Health, Hudson Institute of Medical Research, Clayton, VIC 3168, Australia, FlowCore, Technology Research Platforms, Monash University, Clayton, VIC 3800, Australia
Published online on: July 23, 2018 https://doi.org/10.3892/ol.2018.9193
Pages: 4721-4728

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Endometrial cancer (EC) is the most commonly diagnosed gynecological malignancy in Australian women. Notably, its incidence and mortality rate is increasing. Despite this, there are limited treatment options for EC. Galectin‑7 regulates tumorigenesis in numerous epithelial cancer types, but the role of galectin‑7 has not been investigated in EC. It was hypothesized that galectin‑7 expression would be altered in EC and contribute to the development of EC. Galectin‑7 levels in EC and benign endometrium were quantified by reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) and ELISA. The effect of recombinant galectin‑7 (1 µg/ml) on cell adhesion, proliferation, apoptosis (xCELLigence and flow cytometry), migration (wound healing assay) and gene expression (RT‑qPCR) was investigated using three human EC cell lines (Ishikawa, HEC1A and AN3CA). Galectin‑7 gene and protein expression was significantly elevated in Grade 3 EC, compared with benign tissues. Galectin‑7 was almost undetectable in Ishikawa and AN3CA cells, but highly expressed by HEC1A cells. Recombinant galectin‑7 had no significant effect on cell proliferation or apoptosis in any cell line, but significantly reduced cell adhesion in Ishikawa (at 4 and 6 h) and AN3CA (at 2, 3, 4 and 6 h). Galectin‑7 significantly promoted Ishikawa migration and significantly elevated collagen type IV α 1 chain and intercellular adhesion molecule 1 (ICAM1) gene expression during wound healing. The present study demonstrated that galectin‑7 production increased in EC with increasing cancer grade; therefore, galectin‑7 may promote the metastasis of EC by reducing cell‑cell adhesion and enhancing cell migration.

View Figures

View References

1	Bray F, Ren JS, Masuyer E and Ferlay J: Global estimates of global cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 132:1133–1145. 2013. View Article : Google Scholar : PubMed/NCBI
2	Makker V, Green AK, Wenham RM, Mutch D, Davidson B and Miller DS: New therapies for advanced, recurrent and metastatic endometrial cancers. Gynecol Oncol Res Pract. 4:192017. View Article : Google Scholar : PubMed/NCBI
3	Bilyk O, Coatham M, Jewer M and Postovit LM: Epithelial-to-Mesenchymal transition in the female reproductive tract: From normal function to disease pathology. Front Oncol. 7:1452017. View Article : Google Scholar : PubMed/NCBI
4	Di Cristofano A and Ellenson LH: Endometrial Carcinoma. Annu Rev Pathol. 2:57–85. 2007. View Article : Google Scholar : PubMed/NCBI
5	Pecorelli S: Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 105:103–104. 2009. View Article : Google Scholar : PubMed/NCBI
6	Elola MT, Wolfenstein-Todel C, Troncoso MF, Vasta GR and Rabinovich GA: Galectins: Matricellular glycan-binding proteins linking cell adhesion, migration and survival. Cell Mol Life Sci. 64:1–1700. 2007. View Article : Google Scholar : PubMed/NCBI
7	Dubé-Delarosbil C and St-Pierre Y: The emerging role of galectins in high-fatality cancers. Cell Mol Life Sci. 75:1215–1226. 2018. View Article : Google Scholar : PubMed/NCBI
8	Kaur M, Kaur T, Kamboj SS and Singh J: Roles of Galectin-7 in Cancer. Asian Pac J Cancer Prev. 17:455–461. 2016. View Article : Google Scholar : PubMed/NCBI
9	Lambropoulou M, Deftereou TE, Kynigopolos S, Patsias A, Anagnostopoulos C, Alexiadis G, Kotini A, Tsaroucha A, Nikolaidou C, Kiziridou A, et al: Co-expression of Galectin-3 and CRIP-1 in endometrial cancer: Prognostic value and patient survial. Med Oncol. 33:82016. View Article : Google Scholar : PubMed/NCBI
10	Saussez S and Kiss R: Galectin-7. Cell Mol Life Sci. 63:686–697. 2006. View Article : Google Scholar : PubMed/NCBI
11	Rabinovich GA and Toscano MA: Turning ‘sweet’ on immunity: Galectin-glycan interactions in immune tolerance and inflammation. Nat Rev Immunol. 9:338–352. 2009. View Article : Google Scholar : PubMed/NCBI
12	Cao Z, Said N, Amin S, Wu HK, Bruce A, Garate M, Hsu DK, Kuwabara I, Liu FT and Panjwani N: Galectins-3 and −7, but not Galectin-1, play a role in re-epithelialization of wounds. J Biol Chem. 277:42299–42305. 2002. View Article : Google Scholar : PubMed/NCBI
13	Cao Z, Said N, Wu HK, Kuwabara I, Liu FT and Panjwani N: Galectin-7 as a potential mediator of corneal epithelial cell migration. Arch Ophthalmol. 121:82–86. 2003. View Article : Google Scholar : PubMed/NCBI
14	Evans J, Yap J, Gamage T, Salamonsen L, Dimitriadis E and Menkhorst EM: Galectin-7 is important for nomal uterine repair following menstruation. Mol Hum Reprod. 20:787–798. 2014. View Article : Google Scholar : PubMed/NCBI
15	Menkhorst EM, Gamage T, Cuman C, Kaitu'u-Lino TJ, Tong S and Dimitriadis E: Galectin-7 acts as an adhesion molecule during implantation and increased expression is associated with miscarriage. Placenta. 35:195–201. 2014. View Article : Google Scholar : PubMed/NCBI
16	Demers M, Rose AA, Grosset AA, Biron-Pain K, Gaboury L, Siegel PM and St-Pierre Y: Overexpression of galectin-7, a myoepithelial cell marker, enhances spontaneous metastasis of breast cancer cells. Am J Pathol. 176:3023–3031. 2010. View Article : Google Scholar : PubMed/NCBI
17	Schulz H, Schmoeckel E, Kuhn C, Hofmann S, Mayr D, Mahner S and Jeschke U: Galectins-1, −3, and −7 are prognostic markers for survival of ovarian cancer patients. Int J Mol Sci. 18:E12302017. View Article : Google Scholar : PubMed/NCBI
18	Wang J, Liu Y, Yang Y, Xu Z, Zhang G, Liu Z, Fu H, Wang Z, Liu H and Xu J: High expression of galectin-7 associates with poor overall survival of patients witn non-metastatic clear-cell renal cell carcinoma. Oncotarget. 7:41986–41995. 2016.PubMed/NCBI
19	Labrie M, Vladoiu MC, Leclerc BG, Grosset AA, Gaboury L, Stagg J and St-Pierre Y: A mutation in the carbohydrate recognition domain drives a phenotypic switch in the role of Galectin-7 in prostate cancer. PLoS ONE. 10:e01313072015. View Article : Google Scholar : PubMed/NCBI
20	Kim SJ, Hwang JA, Ro JY, Lee YS and Chun KH: Galectin-7 is epigenetically-regulated tumor supressor in gastric cancer. Oncotarget. 4:1461–1471. 2013. View Article : Google Scholar : PubMed/NCBI
21	Ueda S, Kuwabara I and Liu FT: Suppression of tumor growth by galectin-7 gene transfer. Cancer Res. 64:5672–5676. 2004. View Article : Google Scholar : PubMed/NCBI
22	Livak K and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta DeltaC(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
23	Menkhorst EM, Koga K, Van Sinderen M and Dimitriadis E: Galectin-7 serum levels are altered prior to the onset of pre-eclampsia. Placenta. 35:281–285. 2014. View Article : Google Scholar : PubMed/NCBI
24	Winship AL, Van Sinderen M, Heffernan-Marks A and Dimitriadis E: Chondroitin sulfate proteoglycan protein is stimulated by interleukin 11 and promotes endometrial epithelial cancer cell proliferation and migration. Int J Oncol. 50:798–804. 2017. View Article : Google Scholar : PubMed/NCBI
25	Stefanowicz-Hajduk J, Adamska A, Bartoszewski R and Ochocka JR: Reuse of E-plate cell sensor arrays in the xCELLigence Real-Time Cell Analyzer. Biotechniques. 61:117–122. 2016. View Article : Google Scholar : PubMed/NCBI
26	Labrie M, Valdoiu MC, Grosset AA, Gaboury L and St-Pierre Y: Expression and functions of galectin-7 in ovarian cancer. Oncotarget. 5:7705–7721. 2014. View Article : Google Scholar : PubMed/NCBI
27	Park JE, Chang WY and Cho M: Induction of matrix metalloproteinase-9 by galectin-7 through p38 MAPK signaling in HeLa human cervical epithelial adenocarcinoma cells. Oncol Rep. 22:1373–1379. 2009.PubMed/NCBI
28	Yap J, Salamonsen LA, Jobling T, Nicholls PK and Dimitriadis E: Interleukin 11 is upregulated in uterine lavage and endometrial cancer cells in women with endometrial carcinoma. Reprod Biol Endocrinol. 8:632010. View Article : Google Scholar : PubMed/NCBI
29	Winship AL, Van Sinderen M, Donoghue J, Rainczuk K and Dimitriadis E: Targeting interleukin-11 receptor-α impairs human endomterial cancer cell proliferation and invasion in vitro and reduces tumor growth and metastasis in vivo Mol. Cancer Ther. 15:1–730. 2016. View Article : Google Scholar
30	Campion CG, Labrie M, Lavoie G and St-Pierre Y: Expression of galectin-7 is induced in breast cancer cells by mutant p53. PLoS One. 8:e724682013. View Article : Google Scholar : PubMed/NCBI
31	Piulats JM, Guerra E, Gil-Martin M, Roman-Canal B, Gatius S, Sanz-Pamplona R, Velasco A, Vidal A and Matias-Guiu X: Molecular approaches for classifying endometrial carcinoma. Gynecol Oncol. 145:200–207. 2017. View Article : Google Scholar : PubMed/NCBI
32	Demers M, Couillard J, Giglia-Mari G, Magnaldo T and St-Pierre Y: Increased galectin-7 gene expression in lymphoma cells is under the control of DNA methylation. Biochem Biophys Res Commun. 387:425–429. 2009. View Article : Google Scholar : PubMed/NCBI
33	Bibens-Laulan N and St-Pierre Y: Intracellular galectin-7 expression in cancer cell results from an autocrine transcriptional mechanism and endocytosis of extracellular galectin-7. PLoS ONE. 12:e01871942017. View Article : Google Scholar : PubMed/NCBI
34	Simmen FA, Su Y, Xiao R, Zeng Z and Simmen RC: The Kruppel-like factor 9 (KLF9) network in HEC-1-A endometrial carcinoma cells suggests the carcinogenic potential of dys-regulated KLF9 expression. Reprod Biol Endocrinol. 6:412008. View Article : Google Scholar : PubMed/NCBI
35	Miyake M, Hori S, Morizawa Y, Tatsumi Y, Toritsuka M, Ohnishi S, Shimada K, Furuya H, Khadka VS, Deng Y, et al: Collagen type IV alpha 1 (COL4A1) and collagen type XIII alpha 1 (COL13A1) produced in cancer cells promote tumor budding at the invasion front in human urothelial carcinoma of the bladder. Oncotarget. 8:36099–36114. 2017. View Article : Google Scholar : PubMed/NCBI
36	Kharma B, Baba T, Matsumura N, Kang HS, Hamanishi J, Murakami R, McConechy MM, Leung S, Yamaguchi K, Hosoe Y, et al: STAT1 drives tumor progression in serous papillary endometrial cancer. Cancer Res. 74:6519–6530. 2014. View Article : Google Scholar : PubMed/NCBI
37	Kuessel L, Wenzl R, Proestling K, Balendran S, Pateisky P, Yotova 1st, Yerlikaya G, Streubel B and Husslein H: Soluble VCAM-1/soluble ICAM-1 ratio is a promising biomarker for diagnosing endometriosis. Hum Reprod. 32:770–779. 2017.PubMed/NCBI
38	Vladoiu MC, Labrie M, Létourneau M, Egesborg P, Gagné D, Billard É, Grosset AA, Doucet N, Chatenet D and St-Pierre Y: Design of a peptidic inhibitor that targets the dimer interface of a prototypic galectin. Oncotarget. 6:40970–40980. 2015. View Article : Google Scholar : PubMed/NCBI